OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for AstraZeneca Pharma India's OCF Yield % or its related term are showing as below:
NSE:ASTRAZEN'
s OCF Yield % Range Over the Past 10 Years
Min: -0.07 Med: 0 Max: -0.07
Current: -0.07
During the past 13 years, the highest OCF Yield % of AstraZeneca Pharma India was -0.07%. The lowest was -0.07%. And the median was %.
NSE:ASTRAZEN's OCF Yield % is ranked worse than 70.36% of 1002
companies
in the Drug Manufacturers industry
Industry Median: 3.61
vs NSE:ASTRAZEN: -0.07
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
AstraZeneca Pharma India OCF Yield % Related Terms
AstraZeneca Pharma India OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca Pharma India OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's OCF Yield % distribution charts can be found below:
* The bar in red indicates where AstraZeneca Pharma India's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca Pharma India (NSE:ASTRAZEN) has a OCF Yield % of -0.07 as of Jun. 29, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on AstraZeneca Pharma India and its competitors. According to the industry distribution chart, AstraZeneca Pharma India ranks #705 out of 1002 companies in the Drug Manufacturers industry, placing it in the top 70.4%.
Is AstraZeneca Pharma India's OCF Yield % too high?
AstraZeneca Pharma India's current OCF Yield % is -0.07. Based on the distribution chart, AstraZeneca Pharma India ranks #705 out of 1002 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, AstraZeneca Pharma India has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AstraZeneca Pharma India ranks #705 out of 1002 companies for OCF Yield %. This places AstraZeneca Pharma India in the lower half of its industry. The industry median OCF Yield % is 3.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.61, based on 1,002 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on AstraZeneca Pharma India and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca Pharma India's current OCF Yield % is -0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹10,870.93, compared to a current price of ₹8,391.00 — trading 22.8% below its estimated fair value. The current OCF Yield % is -0.07. AstraZeneca Pharma India's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current OCF Yield % is -0.07 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued.
The current stock price of ₹8,391.00 is trading 22.8% below its estimated GF Value™ of ₹10,870.93.
GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.
Key valuation signals for NSE:ASTRAZEN:
OCF Yield %: -0.07
GF Value™: ₹10,870.93 vs. price of ₹8,391.00 (22.8% below fair value)
No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
92GF Score
Get the complete analysis for NSE:ASTRAZEN
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTRAZEN has been successfully added to your 
